Richmond Pharmacology promotes Patrick Ramiah to Director
Ella Day | September 8, 2025 | Appointment | | Clinical Trial Services, Director of Clinical Project Delivery & Operational Excellence, Richmond Pharmacology, corporate, research and development
Patrick Ramiah has been promoted to Director of Clinical Project Delivery & Operational Excellence at Richmond Pharmacology, effective from 1 September 2025.
Ramiah joined Richmond in 2023 and has been adept at optimising process performance, fostering continuous improvement culture and embedding operational excellence across the organisation and project delivery teams.
Patrick Ramiah commented: “I’m honoured to step into the role of Director of Clinical Project Delivery & Operational Excellence. In my time at Richmond, I’ve been inspired by our collective commitment to embracing continuous improvement as our working culture in delivering outstanding clinical research. I look forward to leading initiatives that elevate our operational standards, establishing robust processes, enhance delivery excellence and ultimately ensure our trials continue to uphold participant safety and data integrity.”
Chief Medical Director, Dr Ulrike Lorch, added: “Patrick’s practical approach to operational excellence and his ability to drive collaboration across teams have strengthened how we implement clinical trials – especially as we navigate an increasingly complex research landscape.
“In this new role, Patrick will lead multidisciplinary teams in bridging the gap between governance and practical implementation, ensuring our trials are delivered compliantly, effectively and with operational clarity.”
This article featured in: October 2025 – The Pharmafile Brief
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
